Saisei Pharma plans clinical study of oral MAF in COVID-19 patients details were featured on some website.
"OSAKA, Japan, May 6, 2020 -- Saisei Pharma today announced plans to initiate an international clinical trial. The decision is based on published preclinical evidence, preliminary reports from independent studies and is supported by data of the safety and efficacy of oral MAF in conditions that require the involvement of macrophages as the front line defense in innate immunity. Prior studies have indicated that oral MAF can activate macrophage activity at least three-fold within a few minutes after application."
Please check the below URL.
finanzen.ch / advfn.com / thechestnutpost.com / benzinga.com